Qiagen (QGEN) was Upgraded to a Buy Rating at Kepler Capital


Kepler Capital analyst David Cerdan upgraded Qiagen (QGEN) to Buy on March 9 and set a price target of EUR51.00. The company’s shares closed last Wednesday at $46.96.

Cerdan has an average return of 3.2% when recommending Qiagen.

According to TipRanks.com, Cerdan is ranked #3870 out of 7358 analysts.

The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $57.48 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $59.00 and a one-year low of $36.16. Currently, Qiagen has an average volume of 943.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts